ClinicalTrials.gg
Status unknownNCT05424887Updated Jul 20, 2022

A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis

A Phase 2 interventional study of AK3280 and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Shanghai Ark Biopharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-07-20.

Sponsored by Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.

Planned enrollment
26th of 60
105 · median 83
Started
2022
with 3 others
Phase 2
21 of 67
7 open now
Registered
22nd of 67
by date

Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 26th largest by planned enrollment of the 60 interventional ones that give a count, is one of 4 that started in 2022, is one of 21 in phase 2, and was the 22nd registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled, multi-center phase II clinical study conducted in China to compare the efficacy and safety of two different dose groups of AK3280 in IPF patients compared to the placebo control group.

Read the detailed description

This study is a randomized, double-blind, placebo-controlled, multi-center phase II clinical study conducted in China to compare the efficacy and safety of two different dose groups of AK3280 in IPF patients compared to the placebo control group. One hundred and five IPF patients who have completed the screening assessment and meet the enrollment requirements will participate in this study and be randomized into 3 treatment groups in a 1:1:1 (35:35:35) ratio: AK3280 200 mg group, AK3280 100 mg group and placebo group; the frequency of medication for each treatment group is twice a day (BID).

This study is divided into a main study and an extension study. The main study includes a 4-week screening period, a 24-week medication observation period, and a 4-week safety follow-up period. The extension study includes a 24-week medication observation period and a 4-week safety follow-up period.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Patients who sign the form before participating in the study.

      1. Patients who understand the importance of complying with the study medication regulations and completing all assessments on time during the entire study process, and agree to strictly abide by the protocol regulations, including the restrictions on concomitant medication during the study process.
      1. Patients aged ≥40 years and ≤80 years at the time of enrollment. 4. Patients diagnosed with IPF within five years before screening (but at least 6 months before the first medication) who meet the standards of the latest American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association (ATS/ERS/JRS/ALAT) 2018 guidelines. The diagnosis of IPF needs to be reconfirmed during the screening assessment.
      1. Patients who have completed the HRCT central review assessment during the screening period or completed the HRCT central assessment within 12 months before screening to confirm the diagnosis of IPF. If the patient is unable to provide pulmonary surgical pathology, the HRCT image must conform to usual interstitial pneumonia to confirm the diagnosis of IPF. Patients who have undergone pulmonary surgical biopsy as part of the initial diagnosis must submit their pathological slices for central review and assessment.
      1. Patients who cannot tolerate pirfenidone or nintedanib and have received no more than 8 consecutive weeks of regular nintedanib or pirfenidone treatment, or patients who, the investigator considers, are not suitable to receive pirfenidone or nintedanib treatment, or patients who refuse to receive pirfenidone or nintedanib treatment.
      1. Patients with %FVC between 50% and 90% (inclusive) at screening, and -corrected %DLco between 30% and 90% (inclusive).
      1. Patients with relatively stable basic lung function, manifested by a \<10% relative difference in FVC values at the screening day and the day before administration. The calculation formula is: (FVC value (L) at screening - FVC value (L) one day before administration) )/(FVC value (L) at screening )× 100% And patients who have no other acute exacerbations of IPF determined by the investigators at the screening day and the day before administration.
      1. Patients whose 6MWT distance is ≥100 m without auxiliary support.

Exclusion criteria

Exclusion Criteria:

    1. Patients suffering from interstitial pneumonia of other known causes.

      1. Patients who plan to undergo lung transplantation within 6 months after screening.
      1. Patients suffering from other lung diseases (such as asthma, , etc.) in addition to IPF.
      1. Patients suffering from any disease whose is less than 12 months other than IPF; or patients requiring long-term medical care, or with limited self-care ability, or the investigator believes that it may affect the patient's participation in the completion of this clinical study, or completion of study-related examinations, or affect safety assessments or efficacy assessments.
      1. Patients who have any evidence or clinically significant adverse physical conditions or abnormal examinations (physical examination, vital signs, or laboratory test abnormalities, etc.) that the investigator believes may affect patient safety or the study endpoint assessments.
      1. Patients with (FEV1)/FVC ratio \<0.7 after the use of bronchodilators at screening.
      1. Patients with a positive bronchodilation test, manifested as a ≥ 12% increase in FEV1 and an absolute increase≥200 mL in FEV1 after the use of bronchodilators.
      1. Patients with peripheral capillary blood oxygen saturation (SpO2) at rest \<88%.
      1. Patients suffering from any clinically diagnosed connective tissue disease, including but not limited to scleroderma, polymyositis/dermatomyositis, systemic lupus erythematosus, and rheumatoid arthritis.
      1. Patients with (NYHA) heart function classification of Class III-IV.
      1. Renal insufficiency or a history of kidney injury; or \<60 mL/min, calculated using the Cockcroft-Gault formula; or patients with end-stage renal disease requiring dialysis.
      1. Patients with diabetes that is not stably controlled at the time of screening ( [HbA1c]> 10%).
      1. Patients hospitalized due to acute exacerbation of IPF within 4 weeks before screening or during the screening period.
      1. Patients currently suffering from malignant tumors or who have been assessed to possibly have malignant tumors (except for localized basal cell carcinoma of the skin or cervical cancer in situ).
      1. Local or systemic infection requiring: i. Hospitalization for ≥24 hours within 4 weeks before screening or during the screening period ii. Use of antibiotics (intravenous, intramuscular injection, oral or inhalation) within 4 weeks before screening or during the screening period
      1. Acute phase of severe lung infection
      1. Active tuberculosis requiring treatment within 12 months before screening
      1. Patients with known immunodeficiency, including but not limited to infection
      1. Patients with acute or chronic hepatitis or patients with known liver cirrhosis
      1. Any of the following circumstances: i. (AST) ≥ 2 × ii. Alanine aminotransferase (ALT) ≥ 2 × upper limit of normal iii. Alkaline phosphatase (ALP) ≥ 2 × upper limit of normal iv. Total ≥1.5 × upper limit of normal v. Severe liver damage or end-stage liver disease
      1. Patients who have received any of the following chronic treatment within 4 weeks before randomization or within 5 half-lives (whichever is longer): i. or immunomodulatory therapy (such as azathioprine, cyclosporine A, cyclophosphamide, D-penicillamine, interferon, tumor necrosis factor-α antagonist) ii. Cytotoxic drugs (such as colchicine) iii. Pirfenidone iv. Tyrosine kinase inhibitors (such as nintedanib) v. Treatment of pulmonary hypertension (such as endothelin receptor antagonists, phosphodiesterase type-5 inhibitors, riociguat, prostacyclin or prostacyclin analogs) vi. N-acetylcystine vii. Other drug viii. Any unapproved drugs for the treatment of IPF, such as interferon-γ, penicillamine, cyclosporine, and mycophenolate
      1. Patients who have received standardized treatment (oral corticosteroids ≤ 10 mg/day are acceptable) within 4 weeks before screening or during the screening period or who require this treatment during the study period.
      1. Patients who have used P-glycoprotein inhibitors or the substrates of transporters OAT1(Organic Anion Transporter 1), OAT3(Organic Anion Transporter 3), OCT2(organic cation transporter 2), MATE2-K(multidrug and toxin extrusion 2-K), and MATE1(multidrug and toxin extrusion 1), with a time interval from the first treatment with the study drug less than five half-lives of the above drugs.
      1. Patients with a history of drinking, drug or chemical abuse, which the investigator judges may harm or affect the patient's complete participation in this study.
      1. Patients with known or suspected peptic ulcers, or patients with palsy, esophageal stenosis, or difficulty swallowing drugs.
      1. Patients who smoked within 3 months before screening or are unwilling to quit smoking during the study period.
      1. Patients whose 12-lead ECG results show (QT interval corrected using Fridericia's formula) interval > 450 msec in men and QTcF interval> 460 msec in women at screening; or patients with a family or personal history of QT interval prolongation syndrome.
      1. Pregnant or breast-feeding women.
      1. Women and men of childbearing age who are unwilling to use effective methods during the study period or at least 3 months after the last administration of the investigational drug.

High-efficiency contraceptive methods for female patients include:

  1. Complete abstinence
  2. Female sterilization operation (bilateral oophorectomy with or without hysterectomy, total hysterectomy or tubal ligation) at least 6 weeks before receiving study treatment.
  3. Male sterilization (at least 6 months before screening). For female patients in the study, the male partners who have undergone vasectomy should be their only partners.
  4. Use of oral contraceptives (estrogen and progesterone), and female patients should have used the same contraceptives steadily for at least 3 months before receiving study treatment.
  5. Injection or implantation of hormonal contraception or placement of intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception with similar efficacy (failure rate \<1%), such as hormonal vaginal ring or transdermal hormonal contraception.

High-efficiency contraceptive methods for male patients include:

  1. Vasectomy (a post-vasectomy record proves that there are no sperm in the ejaculation).
  2. Having sex with a fertile female who uses the aforementioned high-efficiency contraceptive methods.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    100 mg AK3280

    After the 4-week screening period, Eligible subjects will be administered daily 100 mg AK3280 b.i.d. for 24weeks

    Drug: AK3280

  • Experimental
    200 mg AK3280

    After the 4-week screening period, Eligible subjects will be administered daily 200 mg AK3280 b.i.d. for 24weeks

    Drug: AK3280

  • Placebo comparator
    placebo

    There are placebo controls in each dose cohort to assess the safety profile of the study medication. Subjects will be randomized to receive a placebo simultaneously as those subjects randomized to AK3280.

    Drug: Placebo

  • Experimental
    Extension Study Cohort

    The extension study includes a 24-week medication observation period and a 4-week safety follow-up period. Subjects who meet the requirements will enter the extension study after 24 weeks of treatment in the main study. Subjects entering the extension study will continue to orally take AK3280 200 mg for 24 weeks.

    Drug: AK3280

Interventions

  • DrugAK3280

    Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral

  • DrugPlacebo

    Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral

06

What researchers measure

Primary outcomes

  1. After 24 weeks of continuous medication, the absolute decrease in percentage of the predicted FVC from baseline in the AK3280 treatment group compared to the placebo control group.

    Change in percentage of the predicted FVC from baseline

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Assessment of whether AK3280 prolongs the progression-free survival of IPF subjects compared with the placebo control group within 24 weeks and 48 weeks of medication.

    Progression-free survival is defined as the time from randomization to the first occurrence of any of the following events: * The percentage of FVC to the normal expected value (%FVC) achieves an absolute decrease of 10%, or * The percentage of DLco to the normal expected value (%DLco) achieves an absolute decrease of 15%, or * Non-elective hospitalization due to respiratory events * Death

    Time frame: Main study: Up to 24 weeks; Extended study: Up to 48 weeks

  2. The changes from baseline in %DLco, in the AK3280 treatment group compared to the placebo control group

    - After hemoglobin correction, the absolute decrease in %DLco * DLco will be measured at 4 weeks, 12 weeks, 24 weeks, 36 weeks and 48 weeks after the first administration on D1 respectively.

    Time frame: Main study: Up to 24 weeks; Extended study: Up to 48 weeks

  3. The proportion of subjects with a ≥15% absolute decrease in %DLco,in the AK3280 treatment group compared to the placebo control group

    - After hemoglobin correction, the proportion of subjects with a ≥15% absolute decrease in %DLco * DLco will be measured at 4 weeks, 12 weeks, 24 weeks, 36 weeks and 48 weeks after the first administration on D1 respectively.

    Time frame: Main study: Up to 24 weeks; Extended study: Up to 48 weeks

  4. The absolute decrease in forced vital capacity (FVC) from baseline , in the AK3280 treatment group compared to the placebo control group

    FVC will be measured at 4 weeks, 12 weeks, 24 weeks, 36 weeks and 48 weeks after the first administration on D1 respectively.

    Time frame: Main study: Up to 24 weeks; Extended study: Up to 48 weeks

  5. The proportion of patients with a percentage of decrease≥ 10%, ≥ 15% or ≥ 20% in FVC from baseline in each group

    FVC will be measured at 4 weeks, 12 weeks, 24 weeks, 36 weeks and 48 weeks after the first administration on D1 respectively.

    Time frame: Main study: Up to 24 weeks; Extended study: Up to 48 weeks

  6. The time to the percentage of decrease in FVC reaching 10% from baseline

    FVC will be measured at 4 weeks, 12 weeks, 24 weeks, 36 weeks and 48 weeks after the first administration on D1 respectively.

    Time frame: Main study: Up to 24 weeks; Extended study: Up to 48 weeks

  7. Within 24 and 48 weeks of medication, the changes from baseline in the 6MWT(six-minute walk test) distance in the AK3280 treatment group compared to the placebo control group

    The 6MWT distance will be measured at 4 weeks, 12 weeks, 24 weeks, 36 weeks and 48 weeks after the first administration on D1 respectively.

    Time frame: Main study: Up to 24 weeks; Extended study: Up to 48 weeks

  8. Within 24 and 48 weeks of medication, the acute exacerbation of IPF subjects - The time from randomization to the first acute exacerbation - The proportion of subjects who experience at least one acute exacerbation

    A subject needs to meet all 3 criteria below to be judged to have acute exacerbation of IPF: * Acute worsening or progression of dyspnea occurs within 1 month (manifested as rapid decline in lung function, worsening of hypoxemia, worsening of irritating dry cough, and worsening of wheezing after exercise, etc.) * Chest HRCT(high-resolution computed tomography) shows new diffuse ground glass opacities (GGO) and/or consolidation opacities in both lungs on the background of the original mesh opacities, honeycomb opacities and other manifestations of usual interstitial pneumonia (UIP) * Heart failure or fluid overload is ruled out

    Time frame: Main study: Up to 24 weeks; Extended study: Up to 48 weeks

  9. Within 24 and 48 weeks of medication, the IPF-related mortality, all-cause mortality in IPF subjects

    Time frame: Main study: Up to 24 weeks; Extended study: Up to 48 weeks

  10. The changes from baseline in the SGRQ(Saint George's Respiratory Questionnaire) total score in the AK3280 treatment group compared to the placebo control group

    Saint George's Respiratory Questionnaire Part 1 : Symptoms component (frequency \& severity) with a 1, 3 or 12-month recall (best performance with 3- and 12-month recall); Part 2: Activities that cause or are limited by breathlessness; Impact components (social functioning, psychological disturbances resulting from airways disease) refer to current state as the recall. Scores range from 0 to 100, with higher scores indicating more limitations.

    Time frame: Main study: Up to 24 weeks; Extended study: Up to 48 weeks

  11. The proportion of subjects with changes from baseline in the SGRQ ≥4 points from baseline

    Scores range from 0 to 100, with higher scores indicating more limitations.

    Time frame: Main study: Up to 24 weeks; Extended study: Up to 48 weeks

  12. Within 24 and 48 weeks of medication, the proportion of patients who have dose adjustments due to AEs in the AK3280 treatment group and the placebo control group

    Time frame: Main study: Up to 24 weeks; Extended study: Up to 48 weeks

  13. Within 24 and 48 weeks of medication, the proportion of subjects who discontinue the medication due to adverse events (AE) in the AK3280 treatment group and the placebo control group

    Time frame: Main study: Up to 24 weeks; Extended study: Up to 48 weeks

  14. Assessment of adverse events

    Time frame: Main study: Up to 24 weeks; Extended study: Up to 48 weeks

  15. Assessment of serious adverse events (SAEs)

    Time frame: Main study: Up to 24 weeks; Extended study: Up to 48 weeks

  16. Number of participants with abnormal vital signs

    Vital signs: include pulse, respiration, body temperature and blood pressure

    Time frame: Main study: Up to 24 weeks; Extended study: Up to 48 weeks

  17. Number of participants with abnormal Physical examination findings

    Physical examination : include height, weight, skin, head and neck, mouth, chest, abdomen, lymph nodes, nerves and mind, limbs and other sites

    Time frame: Main study: Up to 24 weeks; Extended study: Up to 48 weeks

  18. Number of participants with abnormal 12-lead ECG readings

    Time frame: Main study: Up to 24 weeks; Extended study: Up to 48 weeks

  19. Number of participants with abnormal laboratory test results

    Laboratory tests:include blood routine examination, blood biochemistry ,urine routine test

    Time frame: Main study: Up to 24 weeks; Extended study: Up to 48 weeks

  20. Pharmacokinetic endpoint:The maximum plasma drug concentration (Cmax) of AK3280 and AK3280 M2

    Time frame: Day 1 and Day 7

  21. Pharmacokinetic endpoint:Time to peak (Tmax) of AK3280 and AK3280 M2

    Time frame: Day 1 and Day 7

  22. Pharmacokinetic endpoint:Area under the plasma drug concentration-time curve from 0 hour to 12 hours (AUC0-12h) of AK3280 and AK3280 M2

    Time frame: Day 1 and Day 7

  23. Pharmacokinetic endpoint:Area under the plasma drug concentration-time curve extrapolated from 0 hour to infinity (AUC0-∞) of AK3280 and AK3280 M2

    Time frame: Day 1 and Day 7

  24. Pharmacokinetic endpoint:Oral clearance (CL/F) of AK3280 and AK3280 M2

    Time frame: Day 1 and Day 7

  25. Pharmacokinetic endpoint:Oral volume of distribution (Vd/F) of AK3280 and AK3280 M2

    Time frame: Day 1 and Day 7

  26. Pharmacokinetic endpoint:Terminal half-life (t1/2) of AK3280 and AK3280 M2

    Time frame: Day 1 and Day 7

  27. Pharmacokinetic endpoint:Accumulation coefficient of AK3280 and AK3280 M2

    Time frame: Day 1 and Day 7

07

Study locations

1 site
  • China-Japan Friendship Hospital
    Beijing, Beijing 100029, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2022; primary completion for Jul 2024, 24 months later.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 24 months is close to that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2022
First posted
Jun 21, 2022
StartEst.
Jul 2022
Primary completionEst.
Jul 2024
CompletionEst.
Oct 2024
Last update
Jul 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05424887
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jun 21, 2022
Start date
Jul 2022 (estimated)
Primary completion
Jul 2024 (estimated)
Completion
Oct 2024 (estimated)
Last update
Jul 20, 2022

Study contacts

Chao Yu
Contact
chao.yu@arkbiosciences.com
86-15718873093
Jihong Liu
study director · Medical Director
Yan Wu
study chair · Chief Medical Officer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AK3280

Start the discussion